Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (371)	2/2/2016 6:10:55 PM
From: Gary Mohilner	Respond to of 684

I'd suggest adding GNVC to your list. It fell roughly 70% since getting news the hearing trial being run by Novartis was on a hold for safety. I both believe it to be an over-reaction, but also believe that Novartis isn't about to abandon this drug, even if it is determined that higher doses are unsafe to administer. To be blunt, the lower doses of the drug have provided some measurable noises to people who previously lost hearing at the lower dosage levels, but no one is hearing intelligent speech. GNVC is working on a supplementing drug which could make it much more effective, Novartis has rights of first refusal. More importantly, without further testing, no one knows what may happen with multiple dosing, instead of a single dose. Most importantly, for people who're hard of hearing, or using hearing aids, this drug may prove to provide all the improvement needed to bring their hearing to a normal level. It won't happen in the current trial, but I believe once safety is established, even in the lower levels, Novartis and the FDA should be able to come to an agreement on running such a trial. Gary